Page 4 - Cigna Group Express Scripts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

At least four drugmakers are expected to launch new copycat versions of AbbVie's top-selling rheumatoid arthritis drug, Humira, over the next week, but experts expect little change in prices for the treatment even with the new competition. Drugmakers Boehringer Ingelheim, Sandoz and Organon are expected to launch their biosimilars on Saturday, adding to U.S. competition for the drug that started when Amgen released its copy in January. Usually prices fall, often dramatically, when multiple generic versions of a widely used medication enter market.

The FTC said the acquisition would allow Amgen to entrench Horizon’s monopoly on medications for thyroid eye disease and chronic refractory gout.

The $28 billion acquisition would allow Amgen to entrench Horizon’s monopoly on certain medications, the FTC argues.

Agency says a tie-up would stifle competition for the development of treatments for serious illnesses.

While testifying at a US Senate committee hearing on the price of insulin this week, leaders of major insulin producers and pharmacy benefit managers blamed each other for the high cost of insulin